28th Feb 2008 07:00
Hutchison China Meditech Limited28 February 2008 For Immediate Release Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) Notice of 2007 Preliminary Results London, Thursday, 28 February 2008: Chi-Med will be announcing its preliminaryresults for the year ended 31 December 2007 on Wednesday, 19 March 2008. Ends Enquiries Chi-Med Telephone: +852 2121 8200Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571Anthony Carlisle +44 (0) 7973 611 888David Dible +44 (0) 7967 566 919 About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group focusedon traditional Chinese medicine ("TCM") based primarily in China and wasadmitted to trading on the Alternative Investment Market of the London StockExchange in May 2006. Chi-Med operates three core business segments: 1) Chinahealthcare - the manufacture, distribution and marketing of pharmaceuticals andhealth supplements in China; 2) Drug R&D - the discovery and global developmentof novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumerproducts - global retailing and distribution consumer health and personal careproducts derived from TCM and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hutchmed